Page 9 - P4304.1-V108_PS Magazine - Apr 25_Neat
P. 9

This promotional advert was created by Accord Healthcare Ltd and is intended for UK Healthcare Professionals.
 Varenicline Tablets





 0.5mg & 1mg






                                 PSUK is pleased to offer a 40% discount

                                 on Sereflo pMDIs for dispensing practices







              Product               NHS List price 1    PSUK discount        Saving

              Sereflo pMDI                                 40%                £5.99
              25/125mcg                £14.99

              Sereflo pMDI             £19.99              40%                £7.99
              25/250mcg

             Sereflo pMDI can offer a 25mcg salmeterol with 125 or 250mcg fluticasone
             combination more cost-effectively than the market-leading competitors,
             Seretide® and Sirdupla® (salmeterol/fluticasone).  Plus, you can take
                                                       1-3
 •  Initiation pack and maintenance dosing.  advantage of significant additional savings with the PSUK discount.


 Product Presentation
             Sereflo pMDI is indicated for use in adults with asthma 18 years of age and older only. 4,5
 Strength  0.5mg  0.5mg + 1mg  0.5mg + 1mg  1mg  1mg
             Sereflo pMDI is indicated in the regular treatment of patients with moderate to severe asthma
 Pack Size  56  25 (11+14)  53 (11+42)  28  56  where use of a combination product (long-acting β2 agonist and inhaled corticosteroid)
             is appropriate:
 Product Format  film-coated tablet  film-coated tablet  film-coated tablet  film-coated tablet  film-coated tablet  - patients not adequately controlled on a lower strength corticosteroid combination product 4,5
             or
 Legal Category  POM  POM  POM  POM  POM  - patients already adequately controlled on an inhaled corticosteroid in a mid or
             high strength and a long-acting β2 agonist. 4,5
 Pack Dimensions    48mmx116mm   70mmx134mm   134mmx119mm   48mmx116mm   48mmx116mm
 (HxWxD)  x37mm  x22mm  x22mm  x25mm  x37mm  Seretide is a trademark of GSK. Sirdupla is a registered trademark of Mylan.
             pMDI = pressurised metered dose inhaler.
 Shelf Life  24 months  24 months  24 months  24 months  24 months
 PIP Code  127-5338  127-5361  127-5379  127-5353  127-5346  Sereflo  Metered Dose Inhaler (salmeterol xinafoate/fluticasone   with caution in patients with severe cardiovascular disorders or heart rhythm abnormalities and in
                  ®
             propionate)                                             patients with diabetes mellitus, thyrotoxicosis, uncorrected hypokalaemia or with a predisposition to
                                                                     low levels of serum potassium. Prescribers should also be aware of the risk of adrenal suppression
 EAN Code  5012617003249  5012617003256  5012617003263  5012617003270  5012617003287  Prescribing Information   and acute adrenal crisis which may occur in patients on prolonged treatment with high doses of
             Please consult the full Summary of Product Characteristics (SmPC) before prescribing
             Sereflo 25 microgram (μg) salmeterol xinafoate /125 μg or 250 μg fluticasone propionate per actuation   inhaled corticosteroids. Systemic effects may occur with any inhaled corticosteroid and it is important
                                                                     therefore, that the patient is reviewed regularly and the dose of inhaled corticosteroid is reduced to the
 Trade Price¹  £46.40  £23.20  £56.50  £23.20  £46.40  pressurised inhalation, suspension. For both dose strengths the equivalent delivered dose per   lowest dose at which effective control of asthma is maintained. Visual disturbances may be reported
             actuation is 21 μg of salmeterol and the delivered fluticasone propionate is 110 μg, for 125 μg dose
             strength and 220 μg, for 250 μg dose strength. INDICATIONS: For use in adults with asthma 18 years   with steroid use. Patients presenting with blurred vision or other visual disturbances should be
                                                                     considered for referral to an ophthalmologist. Drug Interactions: Concomitant use should be avoided
 1. Accord Proposition Price List February 2025   of age and older only. Sereflo is indicated in the regular treatment of patients with moderate to severe   with; non-selective and selective β blockers, ritonavir and other potent/moderate CYP3A inhibitors,
             asthma where use of a combination product (long-acting β2 agonist and inhaled corticosteroid) is
             appropriate: patients not adequately controlled on a lower strength corticosteroid combination product   unless potential benefit outweighs the risk. Particular caution is advised in acute severe asthma
                                                                     as hypokalaemia may be potentiated by concomitant treatment with xanthine derivatives, steroids
 Please click or scan the QR codes below to access the SPC.  or patients already adequately controlled on an inhaled corticosteroid in a mid or high strength and   and diuretics. See the SmPC for further information on contraindications and precautions.
             a long-acting β2 agonist. POSOLOGY AND ADMINISTRATION: Patients should be instructed
             in the proper use of their inhaler (see SmPC and patient information leaflet). Recommended   PREGNANCY AND LACTATION: Balance risks against benefits. UNDESIRABLE EFFECTS:
             doses in adults 18 years and older - Two inhalations of 25μg salmeterol and 125 μg or 250 μg   Adverse events which have been associated with salmeterol/fluticasone propionate include: Very
 Varenicline Tablets 0.5mg    fluticasone propionate twice daily. A short-term trial of salmeterol and fluticasone propionate may be   common; nasopharyngitis and headache; Common; candidiasis of the mouth and throat, pneumonia,
 Varenicline Tablets 0.5mg  Varenicline Tablets 1mg  & 1mg (initiation pack)  considered as initial maintenance therapy in adults with moderate persistent asthma for whom rapid   bronchitis, hypokalaemia, throat irritation, hoarseness/dysphonia, sinusitis, contusions, muscle
                                                                     cramps, traumatic fractures, arthralgia and myalgia. For other adverse events please consult the full
             control of asthma is essential. In these cases, the recommended initial dose is two inhalations of 25
             μg salmeterol and 50 μg fluticasone propionate twice daily. Note: Sereflo is not available in a lower   SmPC. MARKETING AUTHORISATION HOLDER & PL NUMBERS: Cipla (EU) Ltd. Dixcart House,
             strength product containing salmeterol 25 μg and fluticasone propionate 50 μg. Therefore, when   Addlestone Road, Bourne Business Park, Addlestone, Surrey KT15 2LE. PL 36390/0237 and PL
 Adverse events should be reported.    initiating therapy, or when it is appropriate to titrate down to a dose below 125 μg, an alternative   36390/0238. Legal category: POM. NHS Cost 25 μg/125 μg 1x 120 dose MDI £14.99 and 25 μg/250
 Reporting forms and information can be found    fixed-dose combination of salmeterol and fluticasone propionate containing a lower dose of the   μg 1x 120 doses MDI £19.99. Date of last revision: April 2020.
             inhaled corticosteroid is required. Use of a spacer device; where required in those with difficulties in
 at https://yellowcard.mhra.gov.uk    coordinating actuation of the inhaler with inspiration of breath, it is recommended ONLY for higher   Adverse events should be reported. Reporting forms and  information can
             strength Sereflo containing salmeterol 25 μg and fluticasone propionate 250 μg. Patients should
             continue to use the same make of spacer device (Volumatic or the AeroChamber Plus) as switching   be found at www.mhra.gov.uk/yellowcard or search for MHRA Yellowcard
             between spacer devices can result in changes in the dose delivered to the lungs. See the SmPC
 Adverse events should also be reported to    for further information on initiation, titration down and spacer use. CONTRAINDICATIONS:   in the Google Play or Apple App Store. Adverse events should also be
 Accord-UK LTD on 01271 385257    Hypersensitivity to the active substances or to any of the excipients. SPECIAL WARNINGS AND   reported Cipla (EU) Ltd on  0800 0472144, drugsafety@cipla.com
             PRECAUTIONS: Sereflo should not be used to treat acute asthma symptoms for which a fast- and
 or email medinfo@accord-healthcare.com  short-acting bronchodilator is required. Patients should be advised to have their inhaler to be used
             for relief in an acute asthma attack available at all times. Patients should not be initiated on Sereflo   References.
             during an exacerbation, or significantly worsening or acutely deteriorating asthma. Serious asthma-  1. Dictionary of medicines and devices (dm+d), available at https://www.nhsbsa.nhs.uk/pharmacies-gp-
             related adverse events and exacerbations may occur with Sereflo. Patients should be asked to     practices-and-appliance-contractors/dictionary-medicines-and-devices-dmd (accessed August 2022).
             continue treatment but to seek medical advice if asthma symptoms remain uncontrolled or worsen   2.  British National Formulary, Medicinal forms, available at
             after initiation. Treatment should not be stopped abruptly due to risk of exacerbation. Therapy should     https://bnf.nice.org.uk/medicinal-forms/fluticasone-with-salmeterol.html (accessed August 2022).
             be down-titrated under physician supervision. All inhaled medication containing corticosteroids   3.  MIMS.co.uk (accessed August 2022).
 Document Number:  UK-Gen-Vare-01410  should be administered with caution in patients with active or quiescent pulmonary tuberculosis and   4. Sereflo 25 microgram/125 microgram. Summary of Product Characteristics.
                                                                     5. Sereflo 25 microgram/250 microgram. Summary of Product Characteristics.
             fungal, viral or other infections of the airway. Salmeterol and fluticasone propionate should be used
 Date of Preparation: January 2025  August 2022   CIPSER20220021
               or call us on 01904 558 350                                    MDS Terms Information | PS Magazine    9 9
                                                                                                                 14/03/2025   16:23:10
         P4304.1-V108_PS Magazine - Apr 25.indd   9                                                              14/03/2025   16:23:10
         P4304.1-V108_PS Magazine - Apr 25.indd   9
   4   5   6   7   8   9   10   11   12   13   14